ReviewFrontiers in cardiovascular medicine2025
Serum uric acid level and prognosis of acute coronary syndrome: a systematic review and dose-response meta-analysis.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Uric acid-to-HDL cholesterol ratio and incident stroke: Competing-risk models in the China Health and Retirement Longitudinal Study.Medicine · 2026Article
- Association of metabolic dysfunction-associated steatotic liver disease with coronary plaque vulnerability and prognosis in patients with acute coronary syndrome.BMC cardiovascular disorders · 2026Article
- A linear association between serum uric acid and 28-day and 90-day mortality after veno-arterial extracorporeal membrane oxygenation in patients with acute myocardial infarction complicated by cardiogenic shock.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to perform a systematic review and meta-analysis evaluating the association between serum uric acid (SUA) concentrations and clinical outcomes in individuals diagnosed with acute coronary syndrome (ACS). Methods: PubMed, Web of Science, Embase, and the Cochrane Library were searched up to March 2025. Stata (15.1) was employed to assess heterogeneity, perform sensitivity analyses, evaluate publication bias, and execute subgroup analyses. Results: A total of 40 cohort studies involving 105,609 ACS patients were included. The results showed that patients with high serum uric acid (HSUA) had significantly higher risks of all-cause mortality [Hazard Ratio [HR] = 1.81, 95% confidence interval [CI]: 1.47-2.22, Conclusion: HSUA level is strongly associated with poor clinical outcomes in ACS patients, including mortality and major cardiovascular events. Given the nonlinear relationship with mortality, SUA could serve as a potentially valuable clinical marker. However, further multicenter studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.